Revolutionary VHH antibodies against SARS-CoV-2 now available

We are excited to announce the launch of our latest product – highly effective and reliable nanobodies against SARS-CoV-2, ideal for use in COVID-19 research and diagnostics.

Since the outbreak of COVID-19, Jotbody has recognized the urgent need for effective tools to combat the virus and has taken swift action by establishing a dedicated team of experts focused on developing high-performance quality nanobodies. This team has been working tirelessly to create innovative solutions to support the fight against SARS-CoV-2, leveraging Jotbody’s expertise in nanobody development and production.

Jotbody’s commitment to the global effort against the pandemic is reflected in its investment in this special team, which is entirely dedicated to developing nanobodies that can neutralize the SARS-CoV-2 virus. Check out our latest releases:

• anti-SARS-CoV-2 Spike S1 nanobody
• anti-SARS-CoV-2 RBD nanobody

These nanobodies have the potential to be used in a variety of applications, including rapid diagnostic tests, therapeutic antibodies, and research tools, to support the development of new treatments and diagnostic solutions.

By leveraging the unique properties of nanobodies, Jotbody’s team of experts is developing cutting-edge tools to support the global effort against COVID-19. These nanobodies have several advantages over conventional antibodies, including their small size, high stability, and excellent tissue-penetrating properties, making them ideal candidates for a variety of applications.